Weekly update: October 12, 2020 to October 16, 2020
We identified and now report nine new RCTs on our website comparisons:
Rajasingham et al, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers,
Abella et al, Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers A Randomized Clinical Trial,
Balcells et al, Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial,
Zhao et al, Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size ,
Lemos et al, Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID),
Wu et al, Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial,
Fu et al, evluating the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19,
Dabbous et al, Comparing the applicability of shared room and single room occupancy ,
Ansarin et al, Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial .
The following studies are updated based on the latest published papers:
Beigel et al, evaluating Remdesivir
RECOVERY Horby et al , evaluating hydroxychloroquine
We have also included and presently extracting the following new RCTs:
SOLIDARITY, Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results,
Altay et al, Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19,
In addition to a new vaccine study:
Pu et al, An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine.
Some RCTs were extracted and pending awaiting author’s reply due to missing outcome data.
Follow us on Twitter